1,836 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,836 shares of the company’s stock, valued at approximately $255,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in NBIX. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares during the last quarter. Blue Trust Inc. increased its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. R Squared Ltd bought a new position in Neurocrine Biosciences in the 4th quarter valued at approximately $61,000. UMB Bank n.a. boosted its position in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after buying an additional 309 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Neurocrine Biosciences by 42.0% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock worth $72,000 after buying an additional 157 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In other news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 222,693 shares of company stock worth $32,718,279. Corporate insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on NBIX. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. BMO Capital Markets cut their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Piper Sandler restated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, Barclays upped their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $166.85.

Neurocrine Biosciences Trading Up 1.5 %

NBIX stock opened at $152.42 on Wednesday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $15.43 billion, a price-to-earnings ratio of 40.86 and a beta of 0.33. The company’s 50 day moving average is $137.92 and its 200 day moving average is $131.51.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.